Company intelligence / Profile preview

DNARx

San Francisco, California, United Statesdnarx.net ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

DNARx has demonstrated in mice that a single administration of its HEDGES non-viral DNA gene therapy platform can durably express FDA-approved protein therapeutics, including granulocyte colony stimulating factor and monoclonal antibodies such as rituximab and mepolizumab, at therapeutic levels for extended periods (>575 days in immunocompetent mice), but has not yet reported human clinical trial results and its pipeline is currently preclinical.[2][4]

Therapeutic areas: HematologyEndocrinologyCardiovascularInfectious DiseasesPulmonologyRare DiseasesOncology
Modalities: Gene therapyDNA vaccineDNA encoding mabAAV based gene therapy
Industry: Biotech

Partnerships

Defense Advanced Research Projects Agency (DARPA) research contract for non-viral DNA-encoded gene therapy to protect against pandemic influenza[3]

Beyond the preview

Go deeper on DNARx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNARx.

Explore the full profile